IDH1 and hematopoietic and lymphoid cell neoplasm: Furthermore, among the involved targets, TP53, in all cohorts; IDH1, in hematological cancers, GBM and low-grade glioma (LGG); and PIK3 genes (TCGA and ICGC cohorts), were recurrently altered (Supplementary Fig. 9).